Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Microdermabrasion

Also known as: microdermabrasion, micro derm, crystal peel

A mechanical resurfacing procedure in which abrasive crystals, a diamond-coated tip or a water-and-serum jet are drawn across the skin under vacuum to abrade the stratum corneum. Cosmetic treatment usually removes part of this dead layer, although controlled work shows full-thickness removal is possible at moderate settings.

Evidence status

Limited

Short-term surface smoothing is the most defensible signal, and coarse-grit diamond treatment can induce procollagen markers in photodamaged forearms. No review addresses microdermabrasion alone; Cochrane found no eligible randomised acne-scar trial, while the only acne-scar arm in a later review contained 11 people and should not be counted twice. Most clinical studies are small, uncontrolled or bundle abrasion with topicals, and recent device studies often have manufacturer funding or authorship.

What microdermabrasion is, and the types available#

Microdermabrasion is a superficial mechanical resurfacing procedure. A handpiece draws an abrasive surface across the skin under negative pressure. Crystal systems propel and recover particles, commonly aluminium oxide or sodium chloride; diamond-tip systems use a fixed abrasive surface; hydradermabrasion combines a textured or spiral tip, suction and liquid delivery.

The procedure acts principally on corneocytes. At low pass counts, controlled work found partial-thickness removal of the stratum corneum. Moderate settings can remove its full thickness with little injury below, while heavier exposure can extend into living epidermis. The quantitative pass-by-pass work was performed on rhesus macaque back skin; the human arm involved qualitative assessment of treated forearms.[6, 8]

This distinguishes microdermabrasion from surgical dermabrasion, which intentionally reaches viable epidermis and dermis, and from dermaplaning, which uses a blade rather than an abrasive vacuum handpiece.[12] A single treatment to the buttock skin of 49 people produced no detectable change in stratum-corneum thickness, showing how much the tissue effect depends on the device and exposure used.[6]

Use of microdermabrasion in aesthetic practice#

Microdermabrasion is a non-prescription cosmetic procedure when a device is marketed for a purely cosmetic purpose. A machine is not automatically a medical device under the UK Medical Devices Regulations 2002; status follows the manufacturer's stated intended purpose. US FDA classification or clearance has no UK legal effect.

The JCCP register does not list microdermabrasion among its five registered modalities, so there is no JCCP benchmark competence standard specific to it. Training evidence, device-specific competence, infection-control procedures and named insurance cover therefore remain important local governance records.[16]

England's 2023 licensing consultation did not name microdermabrasion in any proposed tier, and its statutory definition centres on injection, substances penetrating the epidermis, needles, threads, light, electricity, cold or heat rather than purely mechanical abrasion. No non-surgical cosmetic-procedure licensing scheme is in force in England as of August 2026, and the August 2025 response did not allocate individual procedures to green, amber or red tiers. This is a proposal, not current law. Scotland's 2026 Act depends on commencement regulations; Wales' special-procedures scheme covers acupuncture, body piercing, electrolysis and tattooing rather than microdermabrasion. The cited sources do not establish the practitioner-licensing position in Northern Ireland, which requires a separate local check.[3][3, 4]

Aluminium oxide is also an occupational-substance issue. In Great Britain its workplace exposure limits are 10 mg/m³ inhalable dust and 4 mg/m³ respirable dust as eight-hour time-weighted averages, with no short-term limit, skin notation or carcinogen notation assigned. No published treatment-room measurement establishes whether a crystal machine creates a respirable exposure at those levels, and no indexed operator respiratory case is available. The hazard is plausible and unquantified rather than demonstrated.[5][no source found]

Contraindications and cautions#

Treatment is deferred where the skin cannot be assessed or recover predictably: active bacterial, viral or fungal infection; open wounds; acute inflammatory dermatosis; significant barrier impairment; active inflammatory acne in the treatment field; a suspicious or undiagnosed lesion; and a history suggesting abnormal scarring or pigmentary response. Recent procedures or medicines that alter healing belong to the relevant prescriber, treating clinician or manufacturer instructions rather than to a generic interval.

Higher Fitzpatrick phototypes require particular pigment-risk assessment. Published advice favours conservative superficial resurfacing with pigment control and photoprotection, but this is expert recommendation rather than trial evidence, and no study has quantified post-inflammatory hyperpigmentation after microdermabrasion by phototype.[13]

Crystal systems add eye and inhalation exposure considerations. Aluminium oxide particles smaller than 5 microns remained on treated tissue in the depth study: after 80–100 passes they appeared in more than 90% of macaque histological sections, compared with fewer than 5% after 10–50 passes. Human volunteers were assessed qualitatively, so those percentages are not human incidence figures.[8]i

Clinical uses and the evidence behind them#

Surface texture and short-lived smoothing

The clearest measured benefit is immediate surface smoothing. Three-dimensional replica measurement in 23 volunteers found reduced surface irregularity immediately after diamond microdermabrasion, but most of the change had disappeared within 14 days. This supports a transient finish rather than durable remodelling from one treatment.[20]

Pigmentation, photoageing, striae and scars

In the largest clinical series with biopsies, eight weekly treatments produced mainly mild-to-moderate improvements in melasma, acne scars and striae and only mild improvement in photoageing, with no significant change in epidermal thickness. It was an uncontrolled series, so improvement cannot be separated confidently from natural variation, co-interventions or assessor expectation.[11]

Acne-scarring evidence is especially weak. The 11-person acne-scar subgroup within that series is the same arm a later systematic review described as three participants (27.3%) obtaining no benefit after eight sessions and one (9.1%) achieving a good result; the review re-expressed the cohort rather than independently replicating it. Separately, the 2016 Cochrane review pre-specified three microdermabrasion comparisons and found no eligible randomised trial for any of them.[17, 11][2]

Hydradermabrasion

Hydradermabrasion evidence is thin but not empty. A 20-person open-label acne series bundled the procedure with blue LED and included a manufacturer employee among the authors; investigator-rated clear or almost-clear skin rose from 20% to 65%, but the design cannot isolate abrasion from fluid, extraction, topical products or light. A separate 20-person randomised study compared crystal-free microdermabrasion with pneumatic antioxidant-serum delivery against manual application of the same serum and reported structural and clinical change only in the device arm. It did not isolate the abrasion component.[15, 19]

Dermal remodelling

Microdermabrasion can activate a wound-healing molecular cascade, but response depends on exposure. After one gentle treatment, type-I procollagen increased in only 2 of 11 people at 14 days, and the investigators stated that the clinical meaning was unclear. In 40 adults aged 50–83 with photodamaged forearms, coarse-grit diamond microdermabrasion induced type-I and type-III procollagen, heat-shock protein 47 and prolyl 4-hydroxylase; medium grit induced none. No facial site or visible cosmetic endpoint was measured.[6, 7][18]

Microdermabrasion studies are small, with protocols, units and settings that differ between them, leaving a major disparity between how popular the procedure is and how well its efficacy is documented.[12]

Selecting a microdermabrasion system#

Selection begins with the intended purpose and the evidence that belongs to that exact system. Crystal, diamond-tip and hydradermabrasion machines differ in abrasive surface, vacuum control, consumables, cleaning pathway and whether topical delivery or another modality is bundled into the treatment. No randomised crystal-versus-diamond clinical comparison is available.

The recent diamond-tip clinical literature is open-label, single-arm, funded by the manufacturer and authored by its employees. The procedure was bundled with a topical regimen, preventing attribution of the result to the handpiece alone. A crystal-free platform avoids loose crystals but that design feature is not evidence of better clinical efficacy or safety.[14]

Device output and exposure cannot be translated reliably across machines. The manufacturer instructions for the exact handpiece, consumable and intended site govern selection and use. One forearm barrier study's authors recommended two weeks between a described “superficial peeling procedure”; applying that interval to all microdermabrasion devices is an inference rather than a validated universal schedule.[10]i

Adverse effects and their management#

Expected and transient effects

Erythema, tightness, tenderness, dryness and short-lived sensitivity are foreseeable consequences of superficial abrasion. A small comparison found barrier function recovered within 24 hours after aluminium-oxide microdermabrasion, with erythema settling in about one day, versus approximately four days after 30–70% glycolic-acid peels. These figures came from healthy volar-forearm skin and do not define a universal facial recovery time.[10]

Barrier disruption

Transepidermal water loss rose significantly at 24 hours in an eight-person split-face study, then fell below baseline by day 7. The acute rise represents barrier disruption. The later dip is one small uncontrolled observation and does not establish that the procedure strengthens the barrier.[9]

Pigment and tissue injury

Excess exposure may extend injury below the stratum corneum, while inflammation can lead to post-inflammatory hyperpigmentation or, less commonly, hypopigmentation. Persistent erythema, blistering, erosions, unexpected pain, infection or evolving pigment change require treatment to stop and clinical assessment rather than further abrasion.

Crystal exposure

Eye exposure and residual particles are specific to crystal systems. Occupational controls follow the device's closed-loop design, COSHH assessment and manufacturer safety information. The presence of a workplace exposure limit does not establish that a treatment room exceeds it.[5, 8]

Referral and scope boundaries#

Referral is indicated where the presenting concern may be a medical condition, where a lesion is focal or diagnostically uncertain, where acne is inflammatory or scarring and needs medical management, or where melasma-like pigmentation has not been diagnosed. Aesthetic abrasion is not a diagnostic test.

Urgent clinical review is appropriate for spreading infection, blistering or necrosis, severe pain, ocular exposure with ongoing symptoms, or a pigmentary reaction that is rapid, extensive or accompanied by inflammation. A suspected adverse incident involving a medical device follows the manufacturer's reporting pathway and the MHRA Yellow Card system where applicable.

Dermal-depth resurfacing belongs to surgical dermabrasion; chemical injury belongs to chemical peels; blade exfoliation belongs to dermaplaning; and needle injury belongs to microneedling. Those procedures do not inherit microdermabrasion's evidence or risk profile.

Mechanism of action#

Abrasion, rather than vacuum alone, is the principal stimulus. In a mechanistic comparison, negative pressure alone increased MMP-1 and MMP-3 expression at a quantitatively smaller magnitude than abrasion plus suction; the authors concluded that abrasive contact was necessary for the wider remodelling response.[7]

Removing corneocytes temporarily changes surface topography and barrier function. The resulting injury signal can activate matrix-remodelling genes, but a molecular response does not by itself establish visible collagen improvement. The distinction is important because the exposure that produced a convincing procollagen signal was coarse-grit treatment of photodamaged forearm skin rather than routine facial treatment.[6, 18]

Commonly misstated claims#

“Microdermabrasion resurfaces the epidermis.”

Controlled studies locate the primary effect in the stratum corneum. Full-thickness removal of that dead layer is possible at moderate settings, but it is not equivalent to planned removal of living epidermis.[6, 8]

Supported statement: microdermabrasion abrades the stratum corneum; depth varies with the system and exposure.

“Microdermabrasion is proven to build visible collagen.”

Coarse-grit treatment produced genuine procollagen induction in photodamaged forearms, while medium grit did not. The study measured molecular markers rather than a visible facial outcome.[18]

Supported statement: aggressive microdermabrasion can activate a dermal remodelling cascade, but a corresponding cosmetic result has not been established.

“A systematic review proves that it works.”

The 2011 review often cited here searched dermaplaning, oxygen therapy and light therapy rather than microdermabrasion. No systematic review takes microdermabrasion as its sole subject. The broader acne-scar reviews found either no eligible randomised comparison or poor results in one very small arm.[2, 17][1][no source found]

Supported statement: microdermabrasion appears within broader reviews, and its clinical evidence remains limited.

“Diamond-tip systems are safer and more effective than crystal systems.”

No randomised head-to-head clinical trial is available, and airborne aluminium oxide has not been measured during treatment.

Supported statement: the systems remove the crystal-handling question differently; comparative clinical superiority is unestablished.

Areas of remaining uncertainty#

  • Whether repeated treatments produce durable dermal remodelling rather than repeated short-lived injury signals; until clinical endpoints are measured, collagen claims remain limited.
  • How coarse-grit forearm findings translate to facial devices and settings; without a cross-device scale, nominal settings cannot be treated as equivalent.
  • Whether crystal, diamond-tip and hydradermabrasion differ in outcome or adverse-event rate; without head-to-head trials, selection rests on intended purpose, governance and manufacturer information.
  • Whether respirable aluminium oxide is generated in a treatment room and at what concentration; until measured, COSHH control is precautionary rather than evidence of demonstrated harm.
  • The incidence of post-inflammatory hyperpigmentation by phototype; without stratified data, risk must be individualised and cannot be quoted as a percentage.

Frequently asked questions#

Is microdermabrasion the same as dermabrasion?

No. Microdermabrasion primarily abrades the stratum corneum. Dermabrasion is a deeper surgical procedure involving living tissue.

Does suction alone stimulate collagen?

The available mechanistic comparison found a smaller, narrower gene response from negative pressure alone; abrasive contact drove the wider response.[7]

Is diamond-tip treatment better than crystal treatment?

No comparative randomised clinical trial establishes that. The two systems present different consumable and exposure-control considerations.

How often should treatment be performed?

The instructions for the specific device and consumable govern. Evidence from one forearm study cannot supply a universal interval for every platform or treatment site.[10]

Does microdermabrasion strengthen the skin barrier?

No such conclusion follows from the TEWL evidence. The measured immediate effect was barrier disruption; a below-baseline reading at day 7 came from eight participants and remains unexplained.[9]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Pryor L, Gordon CR, Swanson EW, Reish RG, Horton-Beeman K, Cohen SR. Dermaplaning, topical oxygen, and photodynamic therapy: a systematic review of the literature. Aesthetic Plast Surg. 2011 Dec;35(6):1151-9. PMID 21533984.Tier 1Supports: Systematic review performed August 2009 in PubMed using the keywords 'dermaplaning', 'oxygen therapy' and 'light therapy'; 42 English-language peer-reviewed manuscripts identified, screened independently by three plastic surgeons. Verbatim finding: 'The overall amount of scientific data supporting these methods was found to be scarce, anecdotal, and not well documented.' SCOPE LIMIT, load-bearing: microdermabrasion was NOT a search term and is not one of the three modalities reviewed. This paper is frequently cited as if it assessed microdermabrasion; it did not. It is cited here only for what it did and did not cover.Funding / interest: No funding or conflict-of-interest statement published with the abstract record.
  2. Abdel Hay R, Shalaby K, Zaher H, Hafez V, Chi CC, Dimitri S, Nabhan AF, Layton AM. Interventions for acne scars. Cochrane Database Syst Rev. 2016 Apr 3;4(4):CD011946. PMID 27038134; PMCID PMC7069546.Tier 1Supports: Searched to November 2015; 24 RCTs, 789 adult participants; 14 pairwise comparisons of seven interventions plus four combination interventions. Microdermabrasion was explicitly pre-specified in 'Types of interventions', and three planned comparisons involving it (microdermabrasion vs no treatment; vs needling; vs subcision) had no eligible trial. Verified authors' conclusions include both: 'There is a lack of high-quality evidence about the effects of different interventions for treating acne scars because of poor methodology, underpowered studies, lack of standardised improvement assessments, and different baseline variables' and 'The results of this review do not provide support for the first-line use of any intervention in the treatment of acne scars.' The review does include Linkner 2014, a small split-face pilot in which microdermabrasion was applied as a co-intervention on both sides (microdermabrasion + ALA-PDT vs microdermabrasion + vehicle-PDT); the participant numbers for that pilot could not be re-verified from the accessible full text and are therefore not stated here.Funding / interest: Verified from the accessible full text: the review was supported by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, and of the 24 included trials five were supported by industry, four by academic institutions and 15 did not report a funding source. VERIFICATION LIMIT: the per-author 'Declarations of interest' section could not be retrieved on 2 August 2026 — the PMC rendering truncates before it and cochranelibrary.com returned HTTP 403 — so individual author interests are not asserted here.
  3. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England (consultation document). Consultation ran 2 September to 28 October 2023; gov.uk page last updated 7 August 2025.Tier 1Supports: PROPOSAL ONLY — no scheme is in force. Closing date verified verbatim on the page: responses were sought 'until 11:59pm on 28 October 2023'. Sets out a three-tier green/amber/red model. The proposed green list, verified and complete, is: microneedling; mesotherapy; IPL and LED therapies; chemical peels that involve destruction only into viable epidermis; 'no-needle' fillers including pneumatic devices; micropigmentation including microblading and nanoblading; non-ablative laser hair removal; photo rejuvenation. MICRODERMABRASION IS NOT NAMED in the green, amber or red list, nor anywhere in the document (full-text check, 2 August 2026), though each list is prefaced 'includes, but is not limited to'. The scheme's statutory hook is the Health and Care Act 2022 definition of 'cosmetic procedure', verified verbatim as covering '(a) the injection of a substance (b) the application of a substance that is capable of penetrating into or through the epidermis (c) the insertion of needles into the skin (d) the placing of threads under the skin (e) the application of light, electricity, cold or heat' — purely mechanical abrasion fits none of these five limbs. The document also records that MHRA 'intends to bring into scope of the UK medical devices regulations products for which a manufacturer claims only an aesthetic or another non-medical purpose', naming dermal fillers, which confirms such products were not in scope at the time of writing.
  4. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response. gov.uk page updated 7 August 2025.Tier 1Supports: The government's response to the 2023 consultation. It does NOT assign individual procedures to green, amber or red. Verified verbatim: 'we are not proposing at this stage to remove any of the procedures currently included within the scope of the licensing scheme or associated regulation, nor are we proposing to add any further procedures', and on stakeholder concerns, 'We will continue to work with relevant stakeholders to explore these issues to better evaluate the risks associated with procedures.' It states that legislation will be prioritised for the highest-risk procedures (breast, buttock and genital augmentation with fillers) via a further public consultation, while for lower-risk procedures officials will 'continue the work instigated by the previous government to develop and implement local authority licensing'. Microdermabrasion is not mentioned anywhere in the document (full-text search, accessed 2 August 2026). As of 2 August 2026 no licensing scheme is in force in England.
  5. Health and Safety Executive. EH40/2005 Workplace exposure limits, Fourth edition 2020. Containing the list of workplace exposure limits for use with the Control of Substances Hazardous to Health Regulations 2002 (as amended). London: TSO.Tier 1Supports: Table 1 entry, read directly from the PDF text layer on 2 August 2026: 'Aluminium oxides — inhalable dust / respirable dust', CAS 1344-28-1, long-term exposure limit (8-hour TWA reference period) 10 mg/m3 inhalable dust and 4 mg/m3 respirable dust; the short-term (15-minute) columns are blank, so no STEL is assigned; the comments column is blank, so no 'Sk', 'Sen' or 'Carc' notation applies. The synonym table confirms 'Alumina' and 'Alumite' resolve to 'Aluminium oxides'. Cover page confirms 'EH40/2005 (Fourth Edition 2020)'. These are the GB workplace limits that a salon using crystal microdermabrasion is working under via COSHH. SCOPE LIMIT: EH40 sets a limit; it says nothing about what concentration a microdermabrasion treatment room actually reaches, which has not been measured.
  6. Karimipour DJ, Kang S, Johnson TM, Orringer JS, Hamilton T, Hammerberg C, Voorhees JJ, Fisher G. Microdermabrasion: a molecular analysis following a single treatment. J Am Acad Dermatol. 2005 Feb;52(2):215-23. PMID 15692465.Tier 3Supports: In vivo human study, 49 subjects, single microdermabrasion treatment to BUTTOCK skin (not face), with serial biochemical and immunohistological analysis. Rapid elevation of AP-1 and NF-kappaB, IL-1beta, TNF-alpha and MMP-1, MMP-3, MMP-9. Verbatim and load-bearing: 'No alteration in stratum corneum thickness was detected.' Verbatim: 'Two of 11 subjects also demonstrated increased type I procollagen messenger RNA and protein levels 14 days after treatment.' Authors' conclusion, verbatim: microdermabrasion 'activates a dermal remodeling/wound healing cascade with minimal epidermal disruption.' SCOPE LIMITS: single treatment, buttock skin, molecular endpoints only — no clinical outcome measured, and a transcriptional cascade is not a cosmetic result. Read alongside source 18, which used a more aggressive protocol and found a much stronger procollagen response.Funding / interest: No funding or conflict-of-interest statement published with the abstract record; the group is academic (University of Michigan Department of Dermatology).
  7. Karimipour DJ, Kang S, Johnson TM, Orringer JS, Hamilton T, Hammerberg C, Voorhees JJ, Fisher G. Microdermabrasion with and without aluminum oxide crystal abrasion: a comparative molecular analysis of dermal remodeling. J Am Acad Dermatol. 2006 Mar;54(3):405-10. PMID 16488289.Tier 3Supports: Ten subjects, 3-second exposures comparing focal aluminium oxide crystal abrasion plus negative pressure against negative pressure alone. Verified verbatim: negative pressure alone 'resulted in increased gene expression of MMP-1 and MMP-3 but of a quantitatively reduced magnitude when compared with negative pressure with crystal abrasion'. Conclusion, verbatim: 'The abrasive component of microdermabrasion is necessary for stimulating expression of key genes involved in dermal remodeling.' The authors state their own limitation verbatim: 'It is unclear that molecular changes seen with these treatments can result in clinical effect.' SCOPE LIMITS: n=10, 3-second exposure, gene expression only, no clinical endpoint.Funding / interest: No funding or conflict-of-interest statement published with the abstract record; academic group as source 6.
  8. Gill HS, Andrews SN, Sakthivel SK, Fedanov A, Williams IR, Garber DA, Priddy FH, Yellin S, Feinberg MB, Staprans SI, Prausnitz MR. Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur J Pharm Sci. 2009;38(2):95-103. PMID 19559791; PMCID PMC2731013.Tier 3Supports: MIXED-SPECIES STUDY — the species split is load-bearing and was got wrong in an earlier draft of this entry. ANIMAL ARM: all quantitative histology, and the entire pass-count series (10, 30, 50, 80 and 100 passes at 50 kPa), was done on the BACKS OF RHESUS MACAQUES; methods verbatim, 'Quantitative analysis was carried out on biopsies taken from monkeys exposed to mobile-mode of microdermabrasion.' HUMAN ARM: 16 healthy volunteers (6 male, 10 female, aged 19-40, Atlanta), treated on the VOLAR FOREARM — six had mobile mode at 40 kPa with seven passes, and two groups of five had stationary mode at 30 kPa and 45 kPa for 3 seconds. Human biopsies received QUALITATIVE assessment only; the paper reports 'similar tissue removal trends were observed in human volunteers'. DIRECTION OF THE PAPER, which must not be inverted: the abstract states 'these data showed for the first time that at moderate microdermabrasion conditions selective yet full-thickness removal of stratum corneum could be achieved with little damage to deeper skin tissues', and the concluding sentence is 'we conclude that microdermabrasion can selectively remove full-thickness stratum corneum with little damage to deeper tissues and thereby increase skin permeability'. Quantitatively (macaque), at 50 passes 99 per cent of sections showed substantial stratum corneum removal with only 23 per cent showing substantial viable epidermis removal; at 80 and 100 passes there was extensive viable epidermis damage. Verbatim on the low end: 'Small numbers of passes just removes partial-thickness stratum corneum.' Full-thickness removal was recorded from areas 'measuring less than 100 microns up to approximately 1000 microns in width'. Stationary mode did not give selective removal but produced micro-blisters. Aluminium oxide particles characterised by SEM at 100-300 microns, irregular with sharp edges; residual adherent particles were 'less than 5 microns' and, in MACAQUE sections, 'almost always seen after 80 and 100 passes (> 90% of skin sections), but only occasionally present after 10, 30 and 50 passes (< 5% of skin sections)'. Authors' cosmetic-practice caution: avoid large numbers of mobile-mode passes, the stationary mode 'may also need to be avoided' because of micro-blistering, and topical products 'should be used with caution after microdermabrasion, because the stratum corneum thinning may enhance absorption of the topical formulations, leading to increased and possibly adverse effects.' They add these 'should not be taken as formal recommendations'. They also note microdermabrasion is a US FDA class I device and that 'phase III clinical trials demonstrating the safety and efficacy of microdermabrasion have not been done'. SCOPE LIMITS: quantitative depth and particle data are macaque back skin; the human data are forearm and qualitative; the objective was drug delivery, not cosmetic outcome; stencil-controlled passes are not clinical technique.Funding / interest: Verified: National Institutes of Health (R01 EB006369, U01 AI074579) and the Emory Center for AIDS Research. No competing interests disclosed. Independent of any microdermabrasion manufacturer.
  9. Rajan P, Grimes PE. Skin barrier changes induced by aluminum oxide and sodium chloride microdermabrasion. Dermatol Surg. 2002 May;28(5):390-3. PMID 12030870.Tier 3Supports: Split-face study, eight patients. One side aluminium oxide, other side sodium chloride microdermabrasion. TEWL, stratum corneum hydration, pH and sebum measured at baseline, 24 hours and 7 days. Verified verbatim: both crystal types produced 'a statistically significant increase in TEWL at 24 hours', and 'at 7 days, levels of TEWL were decreased to less than baseline'. Hydration increased at 24 hours with both, and 'hydration in NaCl-treated areas remained significantly increased at 7 days'. Authors conclude that 'both NaCl and Al2O3 microdermabrasion alter the epidermal barrier. These changes in epidermal barrier function may be responsible for the clinical improvement following microdermabrasion' — an explicit hypothesis, not a demonstration. SCOPE LIMITS: n=8, single treatment, no untreated control site, 7-day follow-up, sodium chloride (not sodium bicarbonate) was the comparator crystal.Funding / interest: No funding or conflict-of-interest statement published with the abstract record.
  10. Song JY, Kang HA, Kim MY, Park YM, Kim HO. Damage and recovery of skin barrier function after glycolic acid chemical peeling and crystal microdermabrasion. Dermatol Surg. 2004 Mar;30(3):390-4. PMID 15008867.Tier 3Supports: Thirteen healthy women; 30%, 50% and 70% glycolic acid peeling and aluminium oxide crystal microdermabrasion applied to the VOLAR FOREARM (not the face). Both procedures induced significant damage to skin barrier function immediately after the procedure, and the damage was LESS severe after microdermabrasion than after glycolic acid. Verified verbatim: 'The damaged skin barrier function had recovered within 24 hours after both procedures.' Erythema subsided within 1 day after microdermabrasion versus 4 days after glycolic acid. Authors' practical recommendation, verbatim: 'repeating the superficial peeling procedure at 2-week intervals will allow sufficient time for the damaged skin to recover its barrier function.' SCOPE LIMITS: n=13, forearm not face, single treatment, no clinical efficacy endpoint, and the 2-week wording is written about the superficial peeling procedure — extending it to microdermabrasion courses is a reasonable but not literal reading.Funding / interest: No funding or conflict-of-interest statement published with the abstract record.
  11. El-Domyati M, Hosam W, Abdel-Azim E, Abdel-Wahab H, Mohamed E. Microdermabrasion: a clinical, histometric, and histopathologic study. J Cosmet Dermatol. 2016 Dec;15(4):503-513. PMID 27357600.Tier 3Supports: Thirty-eight patients in four groups (melasma, acne scars, striae distensae, photoageing); eight microdermabrasion sessions at weekly intervals; punch biopsies at baseline and after treatment. Verified verbatim: improvement 'in melasma, acne scars, and striae distensae groups was mainly mild to moderate, while in photoaging group was mainly mild'; 'epidermal thickness showed insignificant changes in all groups'; 'decreased melanization and regular distribution of melanosomes in the epidermis were noted in melasma group'; 'increased density of collagen fibers with more regular arrangement in collagen bundles was detected in all candidates of acne scars, striae distensae, and photoaging groups'; 'Orcein stain did not show any significant changes in elastic fibers'. SCOPE LIMITS: uncontrolled, no randomisation, no blinded assessor described, no comparator arm, Egyptian population with phototypes not reported in the abstract. This appears to be the single microdermabrasion study captured by the 2017 systematic review at source 17, which re-expressed its acne-scar arm as 27.3 per cent no benefit and 9.1 per cent good result.Funding / interest: No funding or conflict-of-interest statement is given in the abstract record.
  12. Grimes PE. Microdermabrasion. Dermatol Surg. 2005 Sep;31(9 Pt 2):1160-5; discussion 1165. PMID 16176767.Tier 4Supports: Narrative review (PubMed publication type 'Review'; NOT a systematic review) of efficacy, safety, epidermal barrier function, histopathologic effects, complications, advantages and disadvantages. Author's conclusion, verified verbatim: 'In general, microdermabrasion studies have been conducted in small groups of patients. Protocols, units, and settings have differed. There remains a major disparity between the popularity of microdermabrasion in the public sector and cohesive and comprehensive scientific data documenting the efficacy of the procedure.' SCOPE LIMIT: no stated search strategy, no risk-of-bias assessment, single author.Funding / interest: No funding or conflict-of-interest statement published with the abstract record.
  13. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009 Jun;28(2):77-85. PMID 19608057.Tier 4Supports: Narrative review of melasma and post-inflammatory hyperpigmentation in skin of colour. Verified verbatim: 'Resurfacing procedures that have been used to treat melasma and PIH include chemical peels, microdermabrasion, lasers, and intense pulsed light. These procedures are best used in combination with topical bleaching agents.' Verified recommendation: 'Given the propensity of darker skin to hyperpigment, resurfacing procedures should be used with care and caution. Maximal results are best achieved with repetitive, superficial, resurfacing modalities. In addition, ultraviolet protective measures such as broad-spectrum sunscreens are fundamental.' SCOPE LIMIT: expert opinion, not microdermabrasion-specific, and gives no incidence figure for PIH after microdermabrasion.Funding / interest: No funding or conflict-of-interest statement published with the abstract record. Note for readers: the author is a frequent industry investigator in the pigmentation field; no disclosure accompanies this record either way.
  14. Goberdhan L, Schneider K, Makino ET, Bautista A, Mehta RC. Efficacy and safety of novel topical pigment-correcting regimen with biweekly diamond tip microdermabrasion procedures on facial hyperpigmentation. J Cosmet Dermatol. 2024 May;23(5):1726-1733. PMID 38288515.Tier 4Supports: Twelve-week, OPEN-LABEL, single-arm study; 18 subjects, Fitzpatrick I-IV, mild to severe facial hyperpigmentation including melasma and PIH. Six in-office diamond-tip procedures with a brightening pro-infusion serum, biweekly, PLUS daily home application of a brightening serum and a dark spot cream. Significant improvement from baseline in radiance, tactile roughness and moisturisation/hydration immediately after the first treatment; MASI improved at day 3; overall hyperpigmentation at week 4; verbatim, 'Most (94.1%) subjects were satisfied with treatment.' SCOPE LIMITS, load-bearing: no control or comparator arm, no randomisation, no blinding, n=18, and the device is inseparable from the concurrent at-home topical regimen — the study cannot attribute any of the effect to the microdermabrasion itself. No Fitzpatrick V-VI subjects were enrolled, so this says nothing about the phototypes at highest PIH risk.Funding / interest: Verified from the PubMed record on 2 August 2026: 'The study was funded by Allergan Aesthetics, an AbbVie Company.' All five authors are affiliated with Allergan Aesthetics, an AbbVie Company, Irvine, California, USA — the company that markets the diamond-tip system and the serums tested. Direct commercial interest, both funding and authorship.
  15. Storgard R, Mauricio-Lee J, Mauricio T, Zaiac M, Karnik J. Efficacy and tolerability of HydraFacial clarifying treatment series in the treatment of active acne vulgaris. J Clin Aesthet Dermatol. 2022 Dec;15(12):42-46. PMID 36569524; PMCID PMC9762628.Tier 4Supports: Twelve-week, multicentre, OPEN-LABEL study; 20 adults with mild-to-moderate acne at two US sites; six HydraFacial Clarifying Treatments, one every two weeks. Verified three-step protocol: cleansing and peeling with Activ-4 and GlySal solutions; exfoliation and suction to remove dead skin cells, sebum and debris; blue LED light with Anti-Ox+ hydration. Proportion with a Global Acne Severity Score of clear or almost clear rose from 20% to 65% by investigator assessment (p=0.0027) and from 5% to 55% by patient self-report (p=0.0016). The paper states its own limitation verbatim: 'Due to the nature of the treatment, blinding of neither investigators nor patients was feasible.' SCOPE LIMITS: n=20, no control arm, no randomisation, unblinded, and blue LED plus proprietary solutions are bundled into the protocol so the hydradermabrasion component cannot be isolated.Funding / interest: Verified verbatim: 'No funding was provided for this article.' Disclosure verbatim: 'Dr. Kwala is an employee of The Hydrafacial Company. The other authors report no conflicts of interest relevant to the content of this article.' CORRECTION to an earlier draft of this entry: 'Kwala' is a mis-rendering of the forename of author Jwala Karnik, whose listed affiliation is 'The HydraFacial Company, Long Beach, California' — the manufacturer's interest IS disclosed, it is simply typeset wrongly. Other affiliations: Storgard, Weill Cornell Medical College; Tess Mauricio, Loma Linda University School of Medicine; Zaiac, Mount Sinai Medical Center Miami Beach. The manufacturer is represented in the authorship of the only published HydraFacial acne series.
  16. Joint Council for Cosmetic Practitioners (JCCP). Practitioner Register treatment categories, jccp.org.uk. Accessed 2 August 2026.Tier 4Supports: The JCCP public register search offers exactly five treatment categories, verified from the site's register selector on 2 August 2026: 'Chemical peels and skin rejuvenation'; 'Lasers, IPL and LED treatments'; 'Dermal fillers'; 'Botulinum toxins'; 'Hair restoration surgery'. Elsewhere the site describes its remit as covering 'Injections, Fillers, Lasers, Peels and Hair Restoration Surgery'. Microdermabrasion is not among the categories and does not appear as a searchable modality. The JCCP register is voluntary; the site states it was awarded Professional Standards Authority status in April 2018 and displays the PSA accreditation mark. It is not a statutory regulator. SCOPE LIMIT: absence from the register is a statement about the scope of the register, not a safety judgement about the procedure.
  17. Kravvas G, Al-Niaimi F. A systematic review of treatments for acne scarring. Part 1: Non-energy-based techniques. Scars Burn Heal. 2017 Mar 30;3:2059513117695312. PMID 29799567; PMCID PMC5965325.Tier 2Supports: Systematic literature search of the preceding ten years; 36 relevant articles across subcision (n=10), dermabrasion (n=1), microneedling (n=8), dermal fillers (n=5) and chemical peeling (n=12). The single study filed under 'dermabrasion' is a microdermabrasion study, discussed under that name. The review identifies it as El-Domyati et al. 2016: it is the 11-person acne-scar subgroup from the same 38-person, four-group series recorded at source 11, not an independent cohort. Verbatim and load-bearing: 'Microdermabrasion achieved the least significant results. A total of 27.3% patients did not achieve any benefit despite eight treatment sessions, and only 9.1% achieved good results.' By comparison, 'all patients treated with microneedling achieved some improvement in scar appearance in the range of 31-62%'. Conclusion: the interventions 'have been used with varying degrees of efficacy' and 'further trials with a larger number of patients are necessary'. SCOPE LIMITS: this is a systematic review of acne scarring, NOT of microdermabrasion; its microdermabrasion result is a re-expression of one 11-person arm (the denominators of 27.3% and 9.1% correspond to 3/11 and 1/11 patients); no meta-analysis, no formal risk-of-bias assessment, no PROSPERO registration stated; and the classification of the study as 'dermabrasion' in the results table is a labelling inconsistency in the paper itself.Funding / interest: No funding or conflict-of-interest statement published with the abstract record. Both authors are UK dermatology/laser clinicians with no stated stake in any microdermabrasion device.
  18. Karimipour DJ, Rittie L, Hammerberg C, Min VK, Voorhees JJ, Orringer JS, Sachs DL, Hamilton T, Fisher GJ. Molecular analysis of aggressive microdermabrasion in photoaged skin. Arch Dermatol. 2009 Oct;145(10):1114-22. PMID 19841398.Tier 3Supports: ADDED ON VERIFICATION as a corrective to an over-sceptical reading of source 6. Forty adults aged 50-83 with clinically photodamaged FOREARMS; focal crystal-free microdermabrasion with diamond-studded handpieces of varying abrasiveness; serial biopsies at baseline and multiple times after treatment. Findings: coarse-grit microdermabrasion induced a wound-healing response with significant dermal remodelling, including induction of type I AND type III procollagen and of the collagen production enhancers heat shock protein 47 and prolyl 4-hydroxylase. Load-bearing negative alongside it: dermal remodelling was NOT achieved with the medium-grit handpiece. Conclusion: coarse-grit treatment induces a dermal remodelling cascade similar to that seen in incisional wound healing. SCOPE LIMITS: forearm not face; molecular and histological endpoints only, with NO clinical or cosmetic outcome measured; the protocol is described by its own authors as aggressive and is not routine salon technique; and the grit dependency means the result cannot be generalised to microdermabrasion in general.Funding / interest: No funding or conflict-of-interest statement published with the abstract record; academic group (University of Michigan Department of Dermatology), same group as sources 6 and 7.
  19. Freedman BM. Hydradermabrasion: an innovative modality for nonablative facial rejuvenation. J Cosmet Dermatol. 2008 Dec;7(4):275-80. PMID 19146604.Tier 3Supports: ADDED ON VERIFICATION — this is the only randomised comparison of hydradermabrasion located, and its omission understated the evidence base. Twenty female volunteers aged 34-56, randomised to Group A (crystal-free microdermabrasion with pneumatic application of a polyphenolic antioxidant serum) or Group B (manual application of the same serum only), six treatments 7-10 days apart. Group A showed increased epidermal and papillary dermal thickness, raised polyphenolic antioxidant levels, collagen improvement and decreased fine lines, pore size and hyperpigmentation, with no complications; Group B showed no structural or clinical change. This partially isolates the device from the serum, because both arms received the serum. SCOPE LIMITS: n=20, single-centre, single author, no stated blinding of assessment, no sham-device arm, PubMed publication type 'Randomized Controlled Trial' but the abstract gives no randomisation method, allocation concealment or power calculation; and the platform tested is not identical to any current branded hydradermabrasion system.Funding / interest: No funding or conflict-of-interest statement is published with this record. VERIFICATION NOTE: the sole author is a private-practice surgeon who has published repeatedly on crystal-free and pneumatic device platforms; no commercial relationship is declared either way, and the absence of a disclosure statement is itself a limitation.
  20. Zapletalova A, Pata V, Janis R, Kejlova K, Stoklasek P. Objective measurements of skin surface roughness after microdermabrasion treatment. Skin Res Technol. 2017 Aug;23(3):346-353. PMID 28083897.Tier 3Supports: ADDED ON VERIFICATION to put a measurement behind the 'same-day glow' description. Twenty-three volunteers aged 31-67, diamond microdermabrasion, with skin surface roughness assessed objectively by 3D scanning of silicone replicas using the chromatic aberration length technique and analysed by fractal geometry. Finding: irregularities of the skin surface are reduced immediately after exfoliation, but that effect mostly diminishes within 14 days, and the authors conclude the method only leads to improvement of the skin surface immediately after its application. SCOPE LIMITS: n=23, no untreated control site described in the abstract, single treatment, surface texture only — no pigment, scar or wrinkle endpoint.Funding / interest: No funding or conflict-of-interest statement published with the abstract record; Czech academic and national institute of public health affiliations.